School of Medicine
Showing 511-520 of 536 Results
-
George Duran
Cancer Biologist and Laboratory Manager, Medicine - Med/Oncology
Current Role at StanfordCancer biologist specializing in the development of novel chemotherapeutic agents and in mechanisms of drug resistance. Current research ranges from molecular studies to further understand the heterogeneity of T-cell lymphomas, to translational studies of molecular determinants of therapeutic response, and clinical trials that use the body’s immune system to fight cancer cells.
Original research contributions have resulted in the authorship of over eighty publications. -
Timothy Durazzo
Professor of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Current Research and Scholarly InterestsThe mission of the Durazzo BRASS lab is to better understand how the interplay between biomedical, psychological and social factors influence treatment outcome in Veterans and civilians seeking treatment for alcohol and substance use disorders. To accomplish this mission, our multidisciplinary team integrates information from advanced neuroimaging, neurocognitive assessment, psychodiagnostic and genotyping methods to identify the biopsychosocial factors associated with relapse and sustained sobriety. Veteran's Administration and Stanford funded Clinical trials are currently being conducted by the BRASS lab that evaluate repetitive transcranial magnetic stimulation techniques as novel complementary treatments to reduce the high rate of relapse experienced by individuals with alcohol and substance abuse disorders. The ultimate goal of our multidisciplinary research program is to promote the development of more effective biomedical and behavioral treatments for alcohol and substance use disorders through consideration of the brain biology, psychology and social circumstances of each individual.
-
Emmanuel During, MD
Clinical Associate Professor, Neurology & Neurological Sciences
Current Research and Scholarly InterestsImproving diagnostics and therapeutics in RBD, using home ambulatory devices including wearable actigraphy, dry-EEG, to power clinical trials based on objective outcomes of RBD activity.
Controlling symptoms of RBD testing drugs rigorously.
Predicting the course of neurodegeneration using deep phenotyping using clinical and serum biomarkers, measures of autonomic impairment, skin biopsy, microbiome